Market Overview
The Gastric Space Occupying Devices Market is projected to grow from USD 219.2 million in 2024 to approximately USD 299.99 million by 2032, reflecting a compound annual growth rate (CAGR) of 4% during the forecast period.
The market's growth is largely driven by the rising global prevalence of obesity and related comorbidities such as type 2 diabetes, cardiovascular diseases, and joint disorders. As awareness increases regarding the health risks associated with obesity, more patients are turning to minimally invasive weight loss interventions. Gastric space-occupying devices—including intragastric balloons and oral palatal inserts—provide non-surgical, temporary, and reversible solutions for patients who may not be eligible for or are unwilling to undergo bariatric surgery.
Additionally, rising disposable incomes in emerging markets and growing awareness of the health benefits of weight loss are contributing to increased demand. Technological innovations, particularly in device design, materials, and delivery systems, are also enhancing treatment outcomes and safety, further encouraging adoption among both healthcare professionals and patients.
Market Drivers
1. Technological Advancements in Device Design and Materials
Innovation in the field of biocompatible materials and ergonomic device design has significantly improved the safety and efficacy of gastric space-occupying devices. Modern systems are more comfortable, customizable, and easier to deploy.
For example, the Orbera® Intragastric Balloon System from Apollo Endosurgery features adjustable volume and biocompatible materials, allowing for personalized patient treatment plans. Enhanced delivery mechanisms have also reduced the invasiveness of procedures, making them more acceptable to patients and facilitating broader adoption by healthcare providers. These improvements have instilled greater confidence in the technology and are accelerating its global expansion.
Market Challenges
1. High Treatment Costs and Limited Insurance Coverage
A major barrier to the widespread adoption of gastric space-occupying devices is the high cost of treatment. These expenses typically include not only the device itself but also procedural fees, clinical monitoring, and post-treatment care. In many regions, especially in developing countries, this cost burden is compounded by the lack of insurance reimbursement for non-surgical weight loss therapies.
Without sufficient healthcare coverage, patients are often required to pay out of pocket, significantly limiting access to treatment—particularly in cost-sensitive or resource-constrained environments.
Market Segmentation
By Product Type
Gastric Balloons
Oral Palatal Space Occupying Devices
By End User
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
By Region
North America: U.S., Canada, Mexico
Europe: Germany, France, U.K., Italy, Spain, Rest of Europe
Asia Pacific: China, Japan, India, South Korea, Southeast Asia, Rest of Asia Pacific
Latin America: Brazil, Argentina, Rest of Latin America
Middle East & Africa: GCC Countries, South Africa, Rest of MEA
Key Market Players
Allurion Technologies, Inc.
Apollo Endosurgery, Inc.
Endalis
Helioscopie
Lexel Medical
MEDSIL
Obalon Therapeutics, Inc.
ReShape Medical, Inc.
Scientific Intake
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook